execut well strateg prioriti financi object
maintain buy rate tp
estim adjust ep
forward price-to-earnings multipl provid upsid
potenti expect slow
growth rate base
develop pipelin expect result phase
program alzheim diseas catalyst
compani
estim base follow factor strong
growth spinraza biosimilar product strateg
collabor made broaden capabl strong
progress pipelin
deliv strong growth revenu year
revenu estim
total revenu increas
compar growth due
strong global penetr spinraza signific gain
biosimilar busi resili core ms busi
net incom increas due
decreas effect tax rate non-gaap net
incom increas ep
increas compar
non-gaap ep increas
estim
mn except ep
compani name inc tickerbiibstock ratingbuyunchangedindustri viewoverweightpositivepric feb week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha inc| februari
incom statement
non-gapp
per share item
product perform develop
valuat consensu perform
ms revenu includ ocrevu royalti
demonstr resili number patient
ms product global remain rel stabl versu
prior year continu see improv trend
ms busi year-over-year basi
spinraza pioneer collabor ioni
first treatment sma gener double-digit
growth global revenu
blockbust perform driven strong y/i revenu
growth even greater revenu growth
outsid
biosimilar revenu grew
referenc humira sever european market imraldi
gener revenu sinc launch mid-
octob make success launch
biogen shown strong momentum build depth
core growth area beyond alzheim diseas
continu build multipl franchis within neurosci
posit data al highlight
potenti leverag groundbreak scienc address
previous untreat diseas exemplifi
strategi build depth neuromuscular diseas
collabor skyhawk therapeut
aim develop oral splice modul
multipl diseas includ ms sma
recommend buy rate tp
base perform pipelin
expect slow growth rate
base develop pipelin expect
result phase program alzheim diseas
catalyst compani
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend rate n/a forward annual dividend yield n/a trail annual dividend rate n/a trail annual dividend yield n/a year averag dividend yield n/a pay-out dividend date n/a ex-dividend date n/a last split factor new per last split date jan inform biogen inc| februari
incom statement
non-gapp
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg amort incom expens oper profit interest incom special interest minor incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli inc| februari
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom non-curr assets- total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in capital- retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item biogen inc| februari
net cash flow provid oper activ increas compar
increas due increas net incom improv collect
custom collabor higher rel accrual revenue-rel reserv lower overal cash
net cash flow use invest activ declin compar
due increas net proce market secur
net cash use financ activ increas compar
due increas cash use share repurchas
depreciation- defer incom oper increas decreas increas decreas current decreas increas payables- decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu debt- issuanc capit stock- repurchas capit payment dividends- financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end inc| februari
report solid revenu growth year led continu strong
global penetr spinraza signific gain biosimilar busi
resili core ms busi
total revenu increas compar
total product revenu increas
compar total revenu therapeut
program increas compar
revenu decreas compar
cost sale decreas compar
 expens increas
compar non-gaap expens
increas compar
 expens includ relat option exercis ioni
pharmaceut inc develop commerci
antisens oligonucleotid al superoxid dismutas
mutat expens includ relat collabor
research develop servic agreement
compar
compar
sg expens increas compar
non-gaap sg expens increas
compar sg expens increas due
time spend well certain invest across sale market
world-wide medic gener administr expens
amort acquir intang asset increas
compar oper incom decreas
compar expens
compar non-gaap expens
compar
tax rate compar non-
tax rate compar
net incom compar net loss
non-gaap net incom
compar
gaap ep compar non-gaap
ep compar
gaap ep
compar
compar
total revenu increas compar
total product revenu increas
compar increas due higher revenu
spinraza biosimilar product partial off-set net decreas
ms product revenu result decreas interferon product
total revenu anti therapeut program increas
compar increas due
higher royalti revenu sale ocrevu well increas share
pre-tax profit rituxan gazyva
total revenu increas compar
increas due higher contract manufactur
sale increas compar
increas cost sale due higher contract manufactur
shipment drug product drug substanc product provid
strateg partner increas biosimilar sale volum increas
royalti payabl ioni higher sale spinraza partial off-set lower
sale cost associ ms product
 expens increas compar
increas due net charg recogn upon
close ioni agreement
 expens
charg expens
upon close
compar
 expens includ
net charg expens upon close ioni
charg expens upon exercis option obtain
world-wide exclus royalti bear licens ioni develop
up-front charg recogn upon enter collabor
 servic agreement investig use novel
protein degrad platform discov develop potenti new
treatment neurolog diseas
sg expens increas compar
non-gaap sg increas
compar increas due increas
oper spend sale market activ support
market product relat spinraza continu expand
new intern market increas cost incur support
busi develop transact complet current period
oper incom increas compar
tax rate compar
non-gaap tax rate compar
reduct tax rate due favor impact tax act
tax rate transit toll tax expens recogn
enact decemb
net incom increas compar
non-gaap net incom increas compar
net incom favor impact decreas tax
gaap ep increas compar
non-gaap ep increas compar
repurchas share compani common stock
total valu includ share repurchas
total valu
decemb cash cash equival market
secur total note payabl financ
increas
compar
gaap ep increas
compar
increas
compar
tecfidera revenu
increas compar
continu
demand global basi
increas
competit
addit treatment
tecfidera revenu increas compar
total revenu increas
compar
total revenu increas
compar total revenu
decreas compar
decreas due decreas unit sale volum higher
discount allow partial off-set price increas
total revenu rest world increas
compar due increas unit sale volum
favor impact foreign currenc exchang total
revenu rest world increas
compar
continu anticip increas demand global basi
increas competit addit treatment ms expect
sale volum stabil futur period also expect moder volum
growth intern market price reduct certain european
decreas
compar
interferon revenu decreas compar
total revenu decreas
compar
total revenu decreas
compar total revenu increas
compar decreas
 interferon revenu due overal decreas interferon unit
sale volum attribut patient transit
ms therapi
total revenu rest world decreas
compar total revenu rest
world decreas compar
decreas rest world revenu due decreas
interferon unit sale volum patient transit ms
therapi price reduct certain european countri
decreas
compar
decreas rest
world revenu due
decreas interferon
unit sale volum
patient transit
ms therapi
 price
reduct certain
declin demand
global basi
 due
addit
treatment ms
intern
tysabri revenu
decreas
compar
tysabri revenu increas compar
total revenu decreas
compar
total revenu increas
compar total revenu declin
compar decreas
due decreas unit sale volum partial off-set price
increas lower discount allow
total revenu rest world decreas
compar total revenu rest
world declin compar
decreas due recognit prior year period
previous defer
anticip slight declin demand global basi
expect volum declin due increas competit
addit treatment ms includ ocrevu exceed volum
growth intern market
zinbryta revenu
compar
zinbryta revenu
compar
zinbryta revenu declin compar prior
year period due voluntari world-wide withdraw zinbryta rm
march total revenu compar
increas
compar
zinbryta revenu
compar
spinraza revenu increas compar
total revenu increas
compar
total revenu increas
compar total revenu increas
compar
increas revenu due increas unit sale volum
partial off-set higher discount allow
total revenu
 increas
compar
total revenu rest world increas
compar total revenu
rest world increas compar
increas due increas unit sale volum
product continu launch new market around world
benepali flixabi
benepali revenu
rest world
increas
compar
biosimilar revenu
compar prior
commerci agreement samsung bioepi began
recogn revenu sale benepali flixabi third parti
eu began recogn revenu
sale imraldi third parti eu benepali revenu
rest world increas
compar
benepali flixabi
increas biosimilar revenu due increas benepali unit
sale volum launch imraldi
revenu program
rituxan gazyva collabor oper profit
revenu therapeut program
revenu
therapeut program
compar
increas
revenu ant-
program due
launch ocrevu
subsequ
revenu recogn
sale ocrevu
 product revenu grew due increas net sale
rituxan includ rituxan hycela
increas also reflect increas gazyva unit sale volum
increas revenu therapeut program
due launch ocrevu subsequ sale growth
royalti revenu recogn sale ocrevu
opicinumab anti-lingo oral monomethyl fumar prodrug aducanumab mab elenbecestat anti-tau anti-tau mab ionis-maptrx anti-tau -synuclein mab f/k/a sma vixotrigin trigemin vixotrigin small fiber neuropath painneurocognit disordersbiib ampa glibenclamid iv lhi acut ischem stroke natalizumab epilepsydapirolizumab pegol sleotheremerg growth areaspainalzheim diseas dementiaparkinson diseas movement disordersacut neurologyneuromuscular diseas includ sma alscoregrowthareasm neuroimmunologyphas phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase phase inc| februari
januari skyhawk therapeut inc enter
collabor research develop servic agreement pursuant
compani leverag skyhawk skystar technolog
platform goal discov innov small molecul rna
splice modifi ms spinal muscular atrophi sma
paid skyhawk up-front payment may also pay
addit mileston payment well potenti royalti biogen
expect record research develop expens
relat collabor remain portion
up-front payment alloc futur research servic
ad six clinic program neurosci pipelin
includ al
actriia/b ligand trap muscl enhanc diseas sma
option acquir acut ischem stroke ampa
receptor potenti cognit impair associ
schizophrenia cia vixotrigin small fiber neuropathi
neuropath pain
skyhawk
collabor
research develop
pursuant
compani leverag
technolog platform
goal discov
rna splice modifi
atrophi sma
decemb enter collabor
research develop servic agreement investig use
novel protein degrad platform discov develop potenti
new treatment neurolog condit alzheim diseas
ad parkinson diseas
pay total up-front addit
mileston payment well potenti royalti record
research develop expens relat
decemb enrol first patient global phase
studi evalu efficaci safeti extend interv dose eid
natalizumab compar standard interv dose sid patient
decemb receiv feedback food drug
administr fda propos phase develop plan
vixotrigin trigemin neuralgia tgn
plan initi phase program develop vixotrigin
tgn end
decemb plc announc
submit new drug applic nda fda
diroximel fumar novel oral fumar develop
treatment relaps form ms
seek approv diroximel fumar
regulatori pathway nda submiss includ data
phase pivot trial evalu long-term safeti relapsing-remit
ms patient dose diroximel fumar approv biogen
intend market diroximel fumar brand name vumer
name condit accept fda
corpor agtc termin collabor agreement
relat develop aav-bas gene therapi
treatment rare ophthalmolog diseas includ x-link retinoschisi
xlr x-link retin pigmentosa portfolio priorit
decis follow top-line interim six-month data phase clinic
trial xlr demonstr sign clinic activ
termin effect march
decemb report posit phase data interim
analysi random placebo-control single- multiple-ascend
dose studi achiev proof-of-biolog proof-of-concept
investig treatment al mutat
paid ioni one-tim up-front payment exercis
option obtain world-wide exclus royalty-bear licens
develop commerci compani plan add
addit cohort studi potenti support registr
receiv feedback
 food drug
administr fda
propos phase
develop plan
vixotrigin
exercis option
licens develop
decemb dose first patient phase studi
ampa receptor potenti patient cia
decemb dose first patient bioequival studi
test whether exposur level plegridi maintain
intramuscular administr compar subcutan administr
pursu intramuscular formul plegridi goal
reduc inject site reaction
novemb award intern prix galien
best biotechnolog product spinraza first treatment
sma prestigi honor mark seventh prix galien
spinraza follow countri recognit germani itali
belgium-luxembourg netherland
galien given everi two year prix galien intern committe
member recognit excel scientif innov improv
octob present result clinic trial
alzheim diseas ctad meet barcelona spain recent
analys on-going long-term extens lte
phase prime studi aducanumab investig treatment
mild cognit impair due ad mild ad late-break
oral present poster includ data patient treat
aducanumab month data analys show
reduct amyloid plaqu level dose- time-depend
manner measur positron emiss tomographi pet
addit analys exploratori clinic endpoint clinic dementia
rate box cdr-sb mini-ment state examin
mmse suggest continu slow clinic declin month
month result dose arm gener consist
previous report analys studi chang
risk-benefit profil aducanumab
dose first patient
phase studi
ampa
receptor potenti
patient cia
addit analys
dementia rate
box cdr-sb
slow clinic declin
month
present latest data phase clinic studi studi
anti-amyloid beta protofibril antibodi patient
earli ad symposium session titl clinic biomark updat
studi earli alzheim diseas held octob
ctad
studi achiev primari outcom measur
design enabl potenti rapid entri phase
develop base bayesian analysi month treatment
convent statist analysi top-line final result
highest treatment dose demonstr statist signific reduct
brain amyloid measur pet month dose also
show statist signific slow clinic declin
alzheim diseas composit score adcom compar
placebo month
eisai also present analysi clinic outcom measur pre-specifi
subgroup includ posit versu neg patient
expect pipelin progress next month
head-to-head data potenti approv
phase data opicinumab
initi potenti pivot cohort al
phase data anti-tau antibodi
final phase data aducanumab
potenti pivot phase data psp
phase initi trigemin neuralgia
latest data
studi
expect revenu rang
expect ep rang
non-gaap ep rang
tax rate expect rang
capit expenditur expect
rang
non-
ep
rang
execut well strateg prioriti financi object
total revenu increas compar
growth due strong global penetr
spinraza signific gain biosimilar busi resili core ms
strateg
prioriti financi
object
net incom increas due decreas
effect tax rate non-gaap net incom increas
ep increas compar
non-gaap ep increas
biogen shown strong momentum build depth core growth
area beyond alzheim diseas continu build multipl franchis
within neurosci posit data al highlight
potenti leverag groundbreak scienc address previous
untreat diseas exemplifi strategi build depth
neuromuscular diseas movement disord
next month expect sever import data
readout across clinic program multipl sclerosi progress
supranuclear palsi alzheim diseas made strateg
collabor skyhawk therapeut
help broaden capabl across multipl modal
potenti identifi therapeut candid rang disord
believ strong base busi includ deep diversifi
neurosci pipelin posit well take advantag
opportun remain focus alloc capit
effici appropri object maxim return
sharehold long term
alloc capit
effici
appropri
object maxim
return
sharehold long
non- reconcili
non- reconcili
non- reconcili
incom statement
non-gapp
per share item
product perform develop
valuat consensu perform
gross margin compar
net margin improv compar due decreas tax rate
ep growth compar
revenu growth compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc| februari
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale biogen inc| februari
invest flow
mrqfinanci mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqreturn mrqreturn asset biogen inc| februari
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item biogen inc| februari
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc dividends- net chang capit free biogen inc| februari
current price-to-earnings multipl averag price-to-earnings stock price dip
quarter sinc stock price show huge fluctuat past three year trail
expect forward price-to-earnings multipl
incom statement
non-gapp
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock primecap manag vanguard group inc clearbridg invest wellington manag compani fmr iancebernstein aqr capit manag top mutual fund holdersholdersharesd report outvaluevanguard/primecap vanguard total stock market vanguard vanguard specialized-health legg mason clearbridg aggress growth vanguard horizon fund-capit opportun spdr etf ishar nasdaq biotechnolog vanguard institut fund-institut etf tr- qqq tr seri inc| februari
develop enter strateg collabor discov develop potenti new treatment neurolog conditionsjanuari inc announc enter strateg collabor investig use novel protein degrad platform discov develop potenti new treatment neurolog condit alzheim diseas parkinson diseas agreement provid expertis research servic target protein degrad provid neurosci expertis drug develop capabl research potenti target togeth advanc candid develop potenti commerci pay total up-front potenti futur mileston payment plu potenti futur royalti expect record research develop expens relat transact skyhawk announc agreement develop novel small molecul rna splice modifi neurolog diseas targetsjanuari skyhawk therapeut inc announc strateg collabor compani leverag skyhawk skystar technolog platform goal discov innov small molecul treatment patient neurolog diseas option licens therapi result collabor respons develop potenti commerci first patient enrol phase studi evalu extend interv dose eid natalizumab multipl sclerosisjanuari first patient enrol global phase studi evalu efficaci safeti extend interv dose eid everi six week natalizumab compar standard interv dose sid patient relaps multipl sclerosi ms inc announc current commerci brand name tysabri natalizumab mg dose everi four week approv dose regimen alkerm announc submiss new drug applic food drug administr diroximel fumar multipl sclerosisdecemb plc inc announc submit new drug applic nda food drug administr fda diroximel fumar novel oral fumar develop treatment relaps form multipl sclerosi ms seek approv diroximel fumar regulatori pathway nda submiss includ data phase pivot trial evalu long-term safeti relapsing-remit ms rrm patient dose diroximel fumar approv intend market diroximel fumar brand name vumer name condit accept fda confirm upon approv inc| februari
incom statement
non-gapp
per share item
product perform develop
valuat consensu perform
ytd stock perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc| februari
consensu view analyst trend stock
low
compar
average
forward price-to-earnings
average
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonbiibindustri avg avgprice/earn yield inc| februari
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr inc| februari
incom statement
non-gapp
per share item
product perform develop
valuat consensu perform
stock price dip decemb high volum share trade
period surg januari
stock price plung setback patent disput februari
stock saw huge fluctuat past one year surg juli volatil
year
stock gave return rang stock
stock price volatil past given return past
stock surg septemb dip june
crispidea price target base strong perform strong pipelin
strong perform due growth spinraza biosimilar product also made collabor
broaden capabl maintain buy rate stock forward price-to-earnings multipl
ep
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
